|Chennai||Rs. 27770.00 (-0.14%)|
|Mumbai||Rs. 29200.00 (2.31%)|
|Delhi||Rs. 27900.00 (-0.36%)|
|Kolkata||Rs. 28270.00 (1%)|
|Kerala||Rs. 27050.00 (-0.37%)|
|Bangalore||Rs. 27550.00 (1.66%)|
|Hyderabad||Rs. 27770.00 (-0.14%)|
New Delhi: UK-based drug maker GlaxoSmithKline (GSK) is in talks with the Indian government for introducing its patented drug Relenza, which is used for the treatment of Influenza A H1N1 (swine flu).
"Currently, we are in talks with the Indian government for introducing the drug Relenza in the domestic market," GlaxoSmithKline South Asia Vice President and India Managing Director Hasit Joshipura told PTI.
When asked whether the company has applied for drug controller general of India's (DCGI) nod, Joshipura said, Relenza is already registered with the Indian government and it doesn't require fresh approval.
The retail sale of the swine Flu drug, Oseltamivir (Tamiflu) is not permitted in India and the drug can be sold through government hospitals as the treatment and diagnosis of the flu has been carried out by the government itself. Till now, Relenza has not been recommended for patients in the country.